RECRUITINGOBSERVATIONAL
Dynamics of the Anti-factor VIII Antibody Signature During Treatment With Emicizumab
About This Trial
The goal of this observational study is to learn about the changes of antibodies and inhibitors against the coagulation factor VIII in patients with severe hemophilia A receiving emicizumab therapy. No additional visits or procedures are planned. Patients in this study will continue to receive their routine care and analysis will be done from left over samples from routine visits.
Who May Be Eligible (Plain English)
Who May Qualify:
- Severe congenital hemophilia A (CHA)
- Treatment with emicizumab irrespective of any other treatment
- willing to sign a consent form
Who Should NOT Join This Trial:
- No therapy with emicizumab
- Immunosuppressive therapy
- HIV-infection with CD4 (cluster of differentiation 4) cells \<200/µl
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* Severe congenital hemophilia A (CHA)
* Treatment with emicizumab irrespective of any other treatment
* Informed consent
Exclusion Criteria:
* No therapy with emicizumab
* Immunosuppressive therapy
* HIV-infection with CD4 (cluster of differentiation 4) cells \<200/µl
Treatments Being Tested
OTHER
no interventions
no intervention, only 3 different patients groups
Locations (1)
University Hospital Frankfurt, Goethe University
Frankfurt am Main, Hesse, Germany